<DOC>
	<DOCNO>NCT01767090</DOCNO>
	<brief_summary>The main objective study assess efficacy dose-response relationship ASP1707 reduction endometriosis associate pelvic pain . The secondary objective assess safety , tolerability , Pharmacokinetics ASP1707 , dose response relationship ASP1707 reduction E2 ( Estradiol ) , 24-week efficacy ASP1707 reduction endometriosis associate pain 24-week safety tolerability ASP1707 .</brief_summary>
	<brief_title>A Study Assess Effectiveness Safety Different Doses ASP1707 Compared Placebo Endometriosis Associated Pelvic Pain</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Pre menopausal female adult confirm length regular menstrual cycle Surgically diagnose endometriosis Moderate severe endometriosis relate pain Hormonal contraceptive drug effect gynecological endocrinology Surgery endometriosis within 4 week prior entry Uterine myoma Abnormal vaginal bleeding Hysterectomy bilateral oophorectomy Pelvic infection Relevant abnormalities gynecological exam screen Disease chronic abdominal pain nonendometriosis origin Pituitary adenoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>ASP1707</keyword>
	<keyword>Pelvic pain</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Phase 2</keyword>
</DOC>